Abstract
Emerging paradigms mandate discovery of imaging agents for diagnosing Alzheimer's disease (AD) prior to appearance of clinical symptoms. To accomplish this objective, a novel heterocyclic molecule (4) was synthesized and validated as Aβ targeted probe. The agent shows labeling of numerous diffuse Aβ plaques in confirmed AD human brain tissues and traverses the blood-brain barrier to enable labeling of parenchymal Aβ plaques in live mice (APP(±)/PS1(±)) brains.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alzheimer Disease / pathology*
-
Animals
-
Benzothiazoles / chemical synthesis*
-
Benzothiazoles / chemistry
-
Brain / pathology*
-
Coloring Agents
-
Diagnostic Imaging
-
Fluorescent Dyes / chemical synthesis*
-
Fluorescent Dyes / chemistry
-
Humans
-
Male
-
Mice
-
Mice, Transgenic
-
Molecular Structure
-
Plaque, Amyloid / pathology*
-
Positron-Emission Tomography
-
Pyridines / chemical synthesis*
-
Pyridines / chemistry
Substances
-
(E)-5-(2-(6-(2-fluoroethoxy)benzo(d)thiazol-2-yl)vinyl)-N,N-dimethylpyridin-2-amine
-
Benzothiazoles
-
Coloring Agents
-
Fluorescent Dyes
-
Pyridines